GB-251

N/A

Report date: 2024/02/05 13:57:38

Base Information

Drug NameGB-251
Drug Alias Name注射用GB251GB-251NBT-828GB221-NBT828 ADC-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-HER2Tubulin inhibitors
TargetsTubulinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenor Biopharma Co LtdNewbio Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A